Oculis Holding AG announced an in-person and virtual R&D Day on December 8, 2026, to highlight key clinical developments in its late-stage pipeline, including Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmology and neurology. The event will feature presentations on the PREDICT-1 trial for Licaminlimab, with topline results expected by year-end, and updates on Privosegtor's development for optic neuritis and multiple sclerosis relapses. The company will also introduce new neurology experts and hold live Q&A sessions. These developments underscore Oculis' focus on innovative treatments addressing significant unmet medical needs in eye and neurological diseases.
Oculis Holding AG's upcoming R&D Day provides context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 09, 2026 14:11 WIB: out of 150 priced health-sector US stocks, 76 rose and 71 fell. Notable movers include MMED at USD 16.71 with a 1-day change of -13.37% and a typical hold time of 17 days, CGC at USD 0.66 down 12.85% with a 40-day hold, and NUVB at USD 4.16 down 12.05% with a 12-day hold.
DNO ASA announced that its offer to acquire Capricorn Energy plc has lapsed as of November 9, 2026. This means the acquisition attempt will not proceed, impacting DNO's expansion plans in the oil and gas sector. Investors should monitor DNO's next st...
Juniper Research forecasts that losses from fraudulent robocalls in North America will decrease by 33%, from $18.4 billion in 2026 to $12.3 billion in 2031. This decline is attributed to telecom operators adopting advanced fraud prevention technologi...
Oculis Holding AG will hold a Research & Development Day on December 8, 2026, to present key clinical progress on its late-stage drug candidates Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmic conditions including optic neuritis...
OTC Markets Group named Olivier Roguez Vice President, Market Data for the EMEA region to lead business development and market data growth. Roguez brings over 20 years of experience from Cboe Global Markets and other firms, aiming to expand OTC Marke...
VAALCO Energy has completed the First Exploration Phase at Block CI-705 offshore Côte d'Ivoire and received government approval to proceed to the Second Exploration Phase. The block, where VAALCO holds a 70% interest, is located near existing oil fie...
